PTGS2 and Cognitive impairment: This new information by demonstrating the role of COX2 in pathogenesis of cognitive dysfunction in depression makes it not only a valid pharmacological target, since COX2 inhibitors are already widely used, but most importantly represents a unique therapeutic opportunity with a true disease-modifying potential for the treatment of cognitive impairment in depression.